Also known as: IL-15 superagonist
Moderna and Merck advance a Phase 2 trial of mRNA cancer vaccine V940 with pembrolizumab and chemotherapy for metastatic squamous NSCLC. In biliary tract cancer, first-line treatment combines chemotherapy with immunotherapy, while targeted therapy resistance prompts liquid biopsy. ImmunityBio tests a chemotherapy-free NK-cell regimen in non-Hodgkin lymphoma.
ImmunityBio resubmitted its supplemental BLA to the FDA for ANKTIVA in papillary bladder cancer after providing additional data. The company also received encouragement from Saudi regulators to submit a recombinant BCG application and expand ANKTIVA approvals.
Calidi Biotherapeutics presented preclinical data on its RedTail virotherapy platform at the 2026 AACR Immuno-Oncology conference, demonstrating tumor-localized BiTE expression and IL-15 superagonist delivery. The company plans to submit an IND application for CLD-401 by end of 2026.
